SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending following news of Elon Musk's $1 billion stock purchase, signaling confidence in the company's future and sparking a rally among investors. The community is debating whether this is a long-term bullish signal or a short-term pump, with some focusing on the company's potential in robotics and AI, while others point to ongoing concerns about valuation and market competition.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as community members highlight its strong community, real-world applications, and growing holder count. The community emphasizes a 'we don't gamble, we work' ethos, with community-led initiatives and real-world products like Kendu Energy driving excitement. Discussions also focus on positive distribution metrics and anticipation for the next alt-season.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as investors anticipate a potential rate cut decision from the Federal Reserve, while some traders express concerns about overvaluation and a possible "sell the news" event. Community chatter revolves around the sustainability of the current rally, with discussions about market mechanics, potential pullbacks, and the impact of the Fed's actions, as well as signs that insiders are selling.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle ($ORCL) is trending amid speculation around its involvement in a potential TikTok deal, with community members discussing the likelihood and potential impact of such an acquisition. Some traders believe positive news could send the stock soaring, while others express skepticism about the deal's value and sustainability, pointing to concerns about a possible "pump and dump" scenario. The stock's recent volatility, following a significant post-earnings surge, is also fueling debate about its near-term direction.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about the recent death of Charlie Kirk and its implications, sparking debates about political violence and ideological divides. Community members are sharing conflicting narratives surrounding the circumstances and motivations behind the event, with some linking it to broader cultural and political issues. The stock is also seeing general market discussion around potential rate cuts and broader economic conditions.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid retail interest possibly sparked by a congressional disclosure of stock purchases and speculation around future government contracts, drawing comparisons to Palantir ($PLTR). Bullish investors are actively analyzing chart patterns, anticipating a short squeeze, and expressing optimism about the company's AI-driven solutions within the growing AI for defense and security sector.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending due to the withdrawal of a planned share offering, sparking speculation of a potential merger or acquisition and a possible short squeeze, especially with a relatively low float. The community is actively discussing price targets and the potential for significant upward movement, fueled by the reduced risk of dilution. Some traders believe the stock may experience halts and a parabolic run, while others are focused on technical levels and potential breakout points.

Slopana

$SLOPANA.X is gaining traction as the self-proclaimed 'king of digital slop,' capitalizing on the meme coin frenzy within the Solana ecosystem. Community members highlight its strong community, CTO leadership and are actively encouraging others to join before a potential surge, referencing its availability on Phantom Wallet.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics ($GLUE) is trending due to a $5.7 billion deal with Novartis for immune-mediated disease drugs, sparking excitement among investors. The community is discussing the potential for a short squeeze and comparing it to other recent high-flying stocks. Bullish sentiment is fueled by the significant upfront payment and future milestone potential, although some traders remain cautious.

Welcome to Auklora  Dive into the ultimate crypto penguin metaverse! Play, earn, and explore in our cozy Solana-powered world.  Earn $AUK Tokens  Collect coins while playing Auklora and convert them to $AUK tokens. Use our calculator to see how many tokens you can earn!  Create your unique penguin avatar with hundreds of clothing items, accessories, and special effects. Stand out in the crowd!  Explore the beautiful world of Auklora through these stunning screenshots from our community

Auklora

Auklora ($AUK.X) is trending as the community highlights its potential as a "Phantom gem," focusing on accumulation. The project's association with the Phantom chain is sparking interest and driving conversation among investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (ZYME) on Tuesday announced its decision to discontinue clinical development of ZW171, designed to target certain cancers.ZW171 is designed to address cancers driven by Mesothelin, a cell-surface protein overexpressed in certain cancers, including gynecological, thoracic, and digestive system cancers. The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.At the time of writing, <a href="https://stocktwits.com/symbol/ZYME">ZYME stock</a> was down by over 17% in Tuesday’s pre-market session. On Stocktwits, retail sentiment around ZYME stock, however, rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:655/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_8_57_28_AM_png_feb9611316.webp" alt="ZYME's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="655" height="61"><figcaption>ZYME's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>After establishing a maximum tolerated dose in the early-stage trial, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-decision-discontinue-clinical-development">determined</a> that further dose escalation would be unlikely to support a benefit-risk profile consistent with the company’s intent to develop it as a standalone therapy.While ongoing participants in the trial will continue treatment at the discretion of their investigator, participants who have discontinued treatment will continue safety follow-up as per the study protocol, Zymeworks said.Zymeworks CEO Kenneth Galbraith said that the outcome is “disappointing” given the promising preclinical activity observed with ZW171.“We continue to advance our broader product pipeline, including the ongoing Phase 1 trial of ZW191 and the initiation of a Phase 1 study for ZW251 expected in 2025. We are also preparing an IND filing for ZW209, our DLL3-directed trispecific T cell engager, planned in the first half of 2026,” he added.&nbsp;ZYME stock is up by 1% this year and nearly 29% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/merck-investigational-drug-shows-reduction-in-cholestrol-in-late-stage-trial/chv6ol3Rdnp">Merck’s Investigational Drug Shows Reduction In Cholesterol In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.

Equity

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.


Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

Shares of Zymeworks Inc. (ZYME) were in the spotlight on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-nmpa-approval-zanidatamab-china-adults">announced</a> that the National Medical Products Administration (NMPA) in China approved Zanidatamab, a bispecific antibody it developed, for the treatment of patients with a type of biliary tract cancer (BTC).The approval is for the treatment of patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer, a diverse group of cancers that affect the bile ducts and gallbladder.Zymeworks’ collaboration partner, BeOne Medicines (formerly BeiGene), obtained conditional approval under the terms of its license and collaboration agreement with Zymeworks in the region.The continued approval of the therapy for BTC will depend on confirmation of clinical benefit through ongoing confirmatory trials, the company said.The U.S. Food and Drug Administration (FDA) approved the therapy for BTC in November. &nbsp;The incidence rate of BTC is on the rise globally, particularly in Asia, the company said, while also noting that BTC accounts for approximately 3% of all digestive system tumors.Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of Zanidatamab as part of its agreement with BeOne Medicines.The company is also eligible to receive up to $144 million in additional development and commercial milestones as well as tiered royalties of up to 19.5% of net sales in BeOne Medicine’s territories.On Stocktwits, retail sentiment around ZYME stayed unmoved within the ‘bearish’ territory over the past 24 hours while message volume dipped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_7_14_43_AM_png_38718537d5.webp" alt="ZYME's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ZYME's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ZYME">ZYME stock</a> is down by 23% this year but up by about 35% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-says-trump-xi-call-needed-as-talks-with-china-are-a-bit-stalled/ch0MqYuRbMH">Scott Bessent Says Trump-Xi Call Needed As Talks With China Are ‘A Bit Stalled’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines.

TD Cowen initiated coverage of Zymeworks with a ‘Buy’ rating, citing its antibody platforms and highlighting Ziihera (zanidatamab-hrii), a targeted therapy for biliary tract cancer, as a potential blockbuster.The research firm expects critical clinical data in the second half of 2025.TD Cowen anticipates Ziihera royalties will support Zymeworks' pipeline development throughout the next two years.&nbsp;Zymeworks shares closed up 5.2% at $12.43 on Tuesday, holding steady after-hours.In November 2024, the U.S. FDA granted accelerated approval for Ziihera to treat previously treated, unresectable, and metastatic HER2-positive biliary tract cancer (BTC).The approval was based on data from the HERIZON-BTC-01 trial, which showed a 52% objective response rate and a median duration of response of 14.9 months.It also resulted in a $25 million milestone payment to the company, which can achieve further payments up to $500 million from regulatory milestones.&nbsp;Additionally, the company has access to $862.5 million from commercial milestones, along with tiered royalties ranging between 10% and 20%.Jazz Pharmaceuticals markets Ziihera through an exclusive license agreement signed in late 2022 that gives them rights to zanidatamab throughout the U.S., Europe, Japan, and select global markets, except for certain Asia-Pacific regions licensed to BeiGene.&nbsp;Ziihera generated net sales of $2 million for Jazz Pharmaceuticals in the first quarter, while producing $0.2 million in royalties for Zymeworks.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.The stock has declined 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy

The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$15.93
Prev Close	$15.74
Open	$15.75
Dividend Yield	0.00%
50-Day Moving Average	$13.88
Beta	0.76
Avg. Volume	462,468.48
PE Ratio	-16.06

52-Week High	$17.70
52-Week Low	$9.03
Market Capitalization	$1.19B
EPS (Annual)	-$1.62
Price to Book	3.55
Revenue Per Employee	$266,797.20
Enterprise Value/EBITDA	N/A

ZYME
Zymeworks Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZYME News

ZYME Zymeworks Inc